Company · founded 2002
InterveXion Therapeutics (United States)
Little Rock, United States · intervexion.com
- Citations, last 5 years
- 0
- Works, last 5 years
- 2
- h-index
- 27
- Scientists listed
- 0
- Grants since 2016
- 17
Grants received
2022–2025 · cooperative agreement · U01
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder
Misty Ward Stevens · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · cooperative agreement · U01
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder
Misty Ward Stevens · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · cooperative agreement · U01
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder
Misty Ward Stevens · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2021–2024 · cooperative agreement · U01
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · cooperative agreement · U01
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2021–2024 · cooperative agreement · U01
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2020–2023 · cooperative agreement · U01
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2020–2024 · cooperative agreement · U01
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization
Misty Ward Stevens · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2020–2023 · cooperative agreement · U01
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2020–2023 · cooperative agreement · U01
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2020–2023 · cooperative agreement · U01
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2020–2024 · cooperative agreement · U01
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2017–2022 · cooperative agreement · U01
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U01
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · cooperative agreement · U01
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2017–2018 · cooperative agreement · U01
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · cooperative agreement · U01
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy
W Brooks Gentry · InterveXion Therapeutics (United States) · funded by National Institutes of Health
